Cryoport (CYRX) Q2 2026 Earnings Call Transcript
Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.
How this was made
The 30-second read
Why it matters
The call discloses quarterly revenue and profitability progress, segment growth drivers, clinical trial support scale, and reiterated full-year guidance, which together can shift near-term expectations for growth and margins.
Market read
Traders can update CYRX expectations for revenue trajectory, profitability path, and capacity expansion based on the disclosed Q2 operating metrics and the reiterated FY guidance range.
What to watch
Adjusted EBITDA is still small in absolute terms ($0.4M), so investors may scrutinize whether margin expansion is sustainable as new facilities and product launches scale.
Background
Cryoport’s Q2 2026 earnings call focuses on Life Science Services growth, Life Science Products demand (MVE cryogenic systems), and progress toward profitability.
Ticker impact
Cryoport reported Q2 2026 revenue of $49M, positive adjusted EBITDA of $0.4M, and reiterated full-year revenue guidance of $192M to $196M.
Likely supportive near-term bias if investors focus on revenue growth mix and the move to positive adjusted EBITDA, but guidance conservatism may cap upside.
The article includes multiple new datapoints (Q2 revenue, segment growth rates, clinical trial count, adjusted EBITDA) plus a reiterated full-year range, which can drive repricing versus prior expectations. However, the excerpt cuts off before Q&A and does not include consensus comparisons or detailed margin drivers.
Market effects
Supports the cell and gene therapy services supply-chain theme, highlighting demand ramp in biostorage, bioservices, and clinical trial logistics.
Mentions improved demand from the Americas region, which may matter for regional logistics and customer concentration expectations.
Clinical trial count and global facility expansion (Houston, Liège, Paris, Santa Ana) reinforce global scaling capacity for temperature-controlled supply chains.
Counterpoint
Holding the full-year revenue range despite a Q2 beat could signal second-half risk, especially if patient ramp or commercial cell and gene therapy volumes slow.
Key entities
- companyCryoport
Reported Q2 2026 revenue of $49M, positive adjusted EBITDA of $0.4M, and reiterated FY 2026 revenue guidance of $192M to $196M.
- companyOrca Bio
Named as receiving FDA approval for TREGZI, referenced in Cryoport’s commercial cell and gene therapy support context.
- companyVerismo Therapeutics
Selected Cryoport to support two clinical trial KIR-CAR T-cell therapy programs.
